Exemplifying interspecies variation of liposome in vivo fate by the effects of anti-PEG antibodies.
10.1016/j.apsb.2024.07.009
- Author:
Ercan WU
1
;
Juan GUAN
1
;
Yifei YU
2
;
Shiqi LIN
2
;
Tianhao DING
2
;
Yuxiu CHU
2
;
Feng PAN
1
;
Mengyuan LIU
1
;
Yang YANG
2
;
Zui ZHANG
2
;
Jian ZHANG
3
;
Changyou ZHAN
2
;
Jun QIAN
1
Author Information
1. School of Pharmacy, Key Laboratory of Smart Drug Delivery (Fudan University), Ministry of Education & Department of Pharmacy, Huashan Hospital, Fudan University, Shanghai 201203, China.
2. Department of Pharmacy, Shanghai Pudong Hospital, Pudong Medical Center & Department of Pharmacology, School of Basic Medical Sciences & State Key Laboratory of Molecular Engineering of Polymers, Fudan University, Shanghai 200032, China.
3. Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
- Publication Type:Journal Article
- Keywords:
ABC phenomenon;
Anti-PEG antibody;
Complement system;
Interspecies;
In vivo fate;
Lipid;
Liposome;
Nanomedicine
- From:
Acta Pharmaceutica Sinica B
2024;14(11):4994-5007
- CountryChina
- Language:English
-
Abstract:
The different fate of liposomes among species has been discovered and mentioned in many studies, but the underlying mechanisms have not been explored. In the present work, we concentrated on the in vivo fate of PEGylated liposomes (sLip) in three commonly used species (mice, rats, and dogs). It was exhibited that the accelerated blood clearance (ABC) phenomenon and hypersensitivity in large animals (beagle dogs) were much more significant than that in rodents. We demonstrated that anti-PEG IgM (partially) and complement (mostly) determined the elimination of sLip and linked the distinct interspecies performances with the diverse complement capacity among species. Based on the data from animals and clinical patients, it was revealed that the fate of sLip in large animals was closer to that in humans, for the sufficient complement capacity could expose the potential adverse reactions caused by anti-PEG antibodies. Our results suggested that the distinctive interspecies performances of sLip were highly related to the physiological variabilities among species, which should not be overlooked in the innovation and translation of nanomedicines.
